PMV Pharmaceuticals, Inc.

NASDAQ:PMVP

Biotechnology

Healthcare
$1.22 +3.91%

+$0.04 today

Market cap
$65.06M
Beta
1.36
P/E (TTM)
-0.8
EPS (TTM)
-$1.47
52W Low $0.96High $1.88

Volume 0.43M

Average 0.38M

PMVP Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

PMV Pharmaceuticals, Inc.NASDAQ: PMVP

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 23.8% from a year ago

Cash & equivalents stood at $39.13M at the end of Q1 FY2026, down 23.8% from a year earlier and up 3.0% from the prior quarter. Over 3 fiscal years it compounded at -29.5% a year.

Context

  • Cash & equivalents amounted to 40.5% of total assets at the end of Q1 FY2026, up 10.4 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -23.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$39.13M+3.0% QoQ
Last fiscal yearDec 2025
$37.98M-7.1% YoY
Year agoMar 2025
$51.34M-23.8% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.8%——
1 year-7.1%——
3-year CAGR-29.5%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
37.98M USD
Year-over-year change
-7.1%
4-year CAGR
-31.5%

Cash & Equivalents vs competitors

How PMVP compares with its peers on the latest reported figures

  • PMVP's Mar 2026 cash & equivalents of $39.13M is the 5th highest of the 9 companies compared; the peer median is $39.38M.
  • Its year-over-year change of -23.8% is the lowest of 9, against a peer median of +26.6%.
  • Cash & equivalents amounts to 40.5% of total assets for PMVP, versus a peer median of 29.9%.
PMVP Competitors Peer median
Cash & Equivalents for PMVP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMUXImmunic, Inc.Mar 2026$186.63M +1204.7%-47.5%98.4%
TCRXTScan Therapeutics, Inc.Mar 2026$128.06M -16.9%+8.3%63.4%
VXRTVaxart, Inc.Mar 2026$50.75M +76.8%+6.9%28.2%
BMEABiomea Fusion, Inc.Mar 2026$44.69M +24.6%-20.7%96.4%
PMVPPMV Pharmaceuticals, Inc.Mar 2026$39.13M -23.8%-29.5%40.5%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$34.06M -13.0%+12.0%31.6%
CBUSCibus, Inc.Mar 2026$30.33M +28.6%+42.5%9.4%
ATYRaTyr Pharma, Inc.Mar 2026$10.01M -3.4%+2.5%12.6%
RLMDRelmada Therapeutics, Inc.Mar 2026$9.78M +750.3%-13.5%4.2%
Peer median (excluding PMVP) $39.38M+26.6%+4.7%29.9%

Competitors are the stored peer set for PMVP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents172.47M108.3M37.71M40.88M37.98M
Short-term Investments124.7M132.76M165.35M128.58M74.96M
Net Receivables00000
Inventory00000
Other Current Assets822K5.95M4.35M6.2M2.28M
Total Current Assets301.29M247.01M207.41M175.66M115.23M
Property, Plant & Equipment (Net)13.15M20.49M19.05M1.55M1.04M
Goodwill00000
Intangible Assets00000
Long-term Investments16.91M2.5M25.51M13.84M0
Tax Assets00000
Other Non-current Assets221K313K190K235K297K
Total Non-current Assets30.28M23.3M44.74M15.63M1.34M
Total Assets331.57M270.31M252.15M191.29M116.56M
Account Payables3.19M3M3.24M6.58M3.16M
Short-term Debt000352K0
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities3.8M2.9M4.5M5.01M4.53M
Total Current Liabilities12.22M10.83M14.03M14.37M11.42M
Long-term Debt0000435K
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities10.79M13.45M12.43M838K435K
Total Liabilities23.01M24.28M26.46M15.21M11.85M
Common Stock00000
Retained Earnings(167.73M)(241.04M)(310M)(368.71M)(446.45M)
Accumulated OCI(78K)(445K)224K139K84K
Other Stockholders Equity00000
Minority Interest00000
Total Equity308.56M246.03M225.69M176.08M104.71M
Total Debt11.19M13.98M13.29M1.19M838K
Net Debt(161.27M)(94.32M)(24.42M)(39.69M)(37.15M)

PMV Pharmaceuticals, Inc.

NASDAQ:PMVP

Intrinsic Alpha fair value

Locked

Current Price

$1.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.